Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818255 · ClinicalTrials.gov registry record · NA
STIM+: PET Biomarker Education & Disclosure
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 152
- Enrollment target
NCT04818255 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 152 participants.
The verdict
NCT04818255, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
Study Summary
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging. Studies have shown that changes in the brain happen before full symptoms of DAT develop. These changes include a buildup of two proteins within the brain, called amyloid and tau. The two goals of this study are (1) to determine whether patients with mild cognitive impairment or dementia-Alzheimer's type (DAT) are able to demonstrate decisional capacity to engage in PET amyloid and tau disclosure after receiving education; and (2) to assess how patients and care partners react to PET amyloid and tau biomarker disclosure.
Interventions
- BEHAVIORAL PET Biomarker Disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2020-12-10 |
| Est. Completion | 2024-11-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04818255
The ClinicalTrials.gov registry entry for NCT04818255 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET Biomarker Disclosure is the first listed.
NCT04818255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04818255 about?
NCT04818255 is a clinical study titled "STIM+: PET Biomarker Education & Disclosure". When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging. Studies have shown that changes in the brain happen before full symptoms of DAT develop. The...
What is the current status of trial NCT04818255?
This trial is currently completed. It is a NA study. The enrollment target is 152 participants. The study started on 2020-12-10. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT04818255?
The interventions under investigation include: PET Biomarker Disclosure (BEHAVIORAL).
Who is sponsoring clinical trial NCT04818255?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.